Abeona Therapeutics Inc Warrants 2015-19.12.19 on Shs
Exchange: IEX Type: Unknown (wt)Remote Buying of Abeona Therapeutics Inc Warrants 2015-19.12.19 on Shs through IEX is under development on ETFS.com.
Notify Me when it is readyRemote Selling of Abeona Therapeutics Inc Warrants 2015-19.12.19 on Shs through IEX is under development on ETFS.com.
Notify Me when it is ready- Open
- Previous Close
- Bid
- Ask
- Day Range -
- 52 Week Range -
- Volume
- Avg. Volume
- Volume to USD
- Market Cap
- Beta
- PE Ratio
- Latest EPS
- EPS TTM
- Dividend
- Dividend Yield
- Ex-Dividend Date
- Revenue TTM
- Revenue per Share
- Revenue per Employee
- Profit Margin
- Gross Profit TTM
- Total Cash TTM
- Total Debt TTM
- Shares Outstanding
- Float
- Short Interest
- Short Ratio
- Insider Ownership
- Institution Ownership
Autolus Therapeutics plc 2020 Q4 - Results - Earnings Call Presentation via Seeking Alpha
Amgen to buy Five Prime Therapeutics in a deal valued at $1.9 billion to boost cancer treatment portfolio via Yahoo Finance
Amicus Therapeutics started at hold with $13 stock price target at Stifel Nicolaus via MarketWatch
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
Analysis is available when the exchange & market are open.